States on systems of sets that are closed under symmetric difference

We consider extensions of certain states. The states are defined on the systems of sets that are closed under the formation of the symmetric difference (concrete quantum logics). These systems can be viewed as certain set‐representable quantum logics enriched with the symmetric difference. We first show how the compactness argument allows us to extend states on Boolean algebras over such systems of sets. We then observe that the extensions are sometimes possible even for non‐Boolean situations. On the other hand, a difference‐closed system can be constructed such that even two‐valued states do not allow for extensions. Finally, we consider these questions in a σ‐complete setup and find a large class of such systems with rather interesting state properties.     

Coumarinolignans Isolated from the Seeds of Brucea javanica

A new coumarinolignan, cleomiscosin E ( 1 ), together with the known compound cleomiscosin A ( 2 ), has been isolated from the seeds of Brucea javanica (L.) Merr . Their structures were assigned on the basis of spectral studies. These two compounds exhibited potent anti‐inflammatory activities by inhibiting the nitric oxide (NO) production in lipopolysaccharide (LPS)‐activated RAW264.7 macrophages.     

Cohomological relation between Jacobi forms and skew‐holomorphic Jacobi forms

Eichler and Zagier developed a theory of Jacobi forms to understand and extend Maass' work on the Saito‐Kurokawa conjecture. Later Skoruppa introduced skew‐holomorphic Jacobi forms, which play an important role in understanding liftings of modular forms and Jacobi forms. In this paper, we explain a relation between Jacobi forms and skew‐holomorphic Jacobi forms in terms of a group cohomology. More precisely, we introduce an isomorphism from the direct sum of the space of Jacobi cusp forms on and the space of skew‐holomorphic Jacobi cusp forms on with the same half‐integral weight to the Eichler cohomology group of with a coefficient module coming from polynomials.     

Moufang sets of mixed type F4

Moufang sets were introduced by Jacques Tits in order to understand isotropic linear algebraic groups of relative rank one, but the notion is more general. We describe a new class of Moufang sets, arising from so‐called mixed groups of type ${\mathsf{F}}_4$ in characteristic 2, obtained as the fixed point set under a suitable involution.     

Asymmetric total syntheses of heliannuol E and epi-heliannuol E

Asymmetric total syntheses of heliannuol E and epi-heliannuol E were achieved in 10 and 13 steps, respectively, from the commercially available starting materials. The syntheses feature an intramolecular attacking on the sulfate to form the dihydropyran ring of heliannuol E and an acyl transfer-secondary carbocation capture sequence to construct the dihydropyran ring of epi-heliannuol E.     

Generation of anti-trenbolone monoclonal antibody and establishment of an indirect competitive enzyme-linked immunosorbent assay for detection of trenbolone in animal tissues, feed and urine

Trenbolone (TRE) is a steroid used by veterinarians on livestock to increase appetite and body weight. The use of TRE has been restricted because of its harmful side effect for consumers. To effectively control TRE residue in food and food product, a rapid and convenient immunoassay was developed by preparing an anti-TRE monoclonal antibody. The immunogen and coating antigen were prepared by coupling TRE hapten with carrier proteins via 1-ethyl-3-(dimethylaminopropyl)carbodiimide hydrochloride (EDC) method. The optimized method gave an average IC₅₀ value of 0.323 ng mL⁻¹ towards TRE and an average detection limit (LOD) of 0.06 ng mL⁻¹, which is much lower than the maximum residue levels (2.0 ng g⁻¹) accepted by the Joint FAO/WHO Expert Committee on Food Additives (JECFA). The specificity of the antibody was evaluated by measuring cross-reactivity of six structurally related compounds, including 19-nortestosterone (9.7%), testosterone (0.13%), methyltestosterone (<0.01%), methandrostenolone (<0.01%), (+)-dehydroisoandrosterone (<0.001%) and β-estradiol (<0.001%). The recovery rates of the test in detection of TRE-fortified animal tissue, urine and animal feed samples were in the range of 81.3-89.4%, while the intra- and inter-assay coefficients of variation were less than 12.0%.     

Synthesis and Crystal Structure of（2E,6E）-2,6-bis（2,3-dimethoxybenzylidene）cyclohexanone

The new title compound (2E,6E)-2,6-bis(2,3-dimethoxybenzylidene)cyclohexanone (C 24 H 26 O 5,M r=394.45) has been synthesized,and its crystal structure was studied.The title compound crystallizes in the orthorhombic system,space group Pca2 1 with a=17.536(2),b=14.8515(16),c=8.0512(9),V=2096.8(4) 3,Z=4,D c=1.250 g/cm 3,λ=0.71073,μ=0.087 mm-1 and F(000)=840.The structure was solved by direct methods and refined to R=0.0533 and wR=0.1248 from 2727 observed reflections (I > 2σ(Ⅰ)).The title molecules are connected through hydrogen bonds to generate a 3-D supramolecule.The preliminary biological tests showed definitely biological activity for the title compound.     

Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study

E-3810, 6-[[7-[(1-aminocyclopropyl)methoxy]-6-methoxy-4-quinolyl]oxy]-N-methyl-naphthalene-1-carboxamide, is a novel, potent, dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors with antiangiogenic properties, now under early clinical evaluation as an anticancer agent. To investigate its clinical pharmacokinetics, a high-performance liquid chromatography-tandem mass spectrometry method was developed and validated to measure the drug in human plasma on the basis of simple protein precipitation with methanol after addition of deuterated E-3810 as internal standard. The method requires a small volume of sample (100 μl) and is rapid and selective, allowing good resolution of peaks in 5 min. It is sensitive, precise, and accurate, with overall precision, expressed as CV%, always ≤7.1%, accuracy in the range 92.7%-104.4%, and high recovery, close to 100%. The limit of detection is 0.01 ng/ml, and the lower limit of quantitation is 2.0 ng/ml. The assay was validated in the range from the lower limit of quantitation up to 500.0 ng/ml. This is the first method developed and validated for analyzing E-3810 in human plasma. The method has been successfully applied to study E-3810 pharmacokinetics in cancer patients with solid tumors who are receiving daily oral doses of the drug during the phase I trial.